摘要
目的:探讨采用头孢噻肟钠/舒巴坦钠治疗重症呼吸系统感染患者的临床疗效。方法:选取2014年1月—2015年3月于太平镇神岗卫生院就诊治疗的98例重症呼吸系统感染患者作为研究对象,按随机数字表法将患者分为观察组和对照组各49例。对照组患者应用常规方法进行治疗,观察组患者应用头孢噻肟钠/舒巴坦钠实施治疗,对比分析2组患者的临床疗效。结果:对照组患者的总有效率为77.55%(38/49),观察组为91.84%(45/49),2组的差异有统计学意义(P<0.05);对照组患者的致病菌清除率为90.41%(66/73),观察组为95.89%(70/73),2组的差异有统计学意义(P<0.05)。结论:应用头孢噻肟钠/舒巴坦钠治疗重症呼吸系统感染临床疗效显著,病菌清除率高,值得临床推广。
OBJECTIVE： To probe into the clinical efficacy of cefotaxime / sulbactam in treatment of patients with severe respiratory infection. METHODS： 98 patients with severe respiratory infection admitted into Taiping Town Shengang Health Center from Jan. 2014 to Mar. 2015 were selected to be divided into observation group and control group via the random number table,with 49 cases in each group. The control group received conventional therapy,while the observation group were treated with cefotaxime / sulbactam,the clinical efficacy of two groups were compared.RESULTS： The total effective rate of control group was 77. 55%（ 38 /49）,and of observation group was 91. 84%（ 45 /49）,with statistically significant difference（ P〈0. 05）. The pathogenic bacteria clearance of of control group was90. 41%（ 66 /73）,and as for observation group,it was 95. 89%（ 70 /73）,the difference was significant（ P〈0. 05）.CONCLUSIONS： The efficacy of cefotaxime / sulbactam in treatment of patients with severe respiratory infection is significant,with a high pathogenic bacteria clearance,which is worthy of being widely applied in clinic.
出处
《中国医院用药评价与分析》
2015年第12期1575-1577,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
